Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
Rhea-AI Summary
Accuray (NASDAQ: ARAY) granted equity inducement awards under NASDAQ Listing Rule 5635(c)(4) to new executives Paul Miele, Chief Commercial Officer, and David Shin, Chief Legal Officer.
Miele received 650,000 RSUs and 650,000 PSUs; Shin received 375,000 RSUs and 375,000 PSUs, with time-based vesting starting in 2027 and PSU performance periods through fiscal 2028.
Positive
- Equity awards to new CCO and CLO support executive recruitment and retention
- Performance-based units link part of compensation to achieving fiscal 2028 performance criteria
Negative
- All inducement awards are granted outside the existing 2026 equity plan
- Total of 2,050,000 RSUs and PSUs increases future share-based compensation over several years
News Market Reaction – ARAY
In the Jun 1 session, ARAY gained 2.80%, reflecting a moderate positive market reaction. Argus tracked a trough of -10.2% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 15 | Research collaboration | Positive | +8.4% | 10-year master research agreement on adaptive radiation therapy platform. |
| May 06 | Earnings results | Negative | -38.5% | Q3 revenue and margins down year-over-year with guidance withdrawn. |
| Apr 22 | Earnings date set | Neutral | -3.1% | Announcement of upcoming Q3 results release and conference call. |
| Apr 06 | Leadership appointment | Positive | +0.8% | Appointment of new SVP and Chief Commercial Officer to drive growth. |
| Feb 04 | Earnings results | Negative | -20.7% | Q2 revenue decline, margin compression and updated FY2026 guidance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has often produced directionally consistent reactions: positive partnership/leadership items saw gains, while weaker financial results triggered sharp declines.
Over the last few months, ARAY reported weaker fiscal 2026 Q2 and Q3 results, with revenue declines, widened net losses, restructuring charges and guidance withdrawal, which were followed by price drops of -20.68% and -38.55%. In contrast, a 10-year research agreement with the University of Wisconsin and the appointment of a new Chief Commercial Officer saw modest to strong positive moves, including +8.41%. Today’s inducement awards continue the theme of leadership and compensation changes amid a broader operational transformation.
Key Terms
restricted stock units financial
performance based restricted stock units financial
nasdaq listing rule 5635(c)(4) regulatory
equity incentive plan financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
As material inducements to Mr. Miele and Mr. Shin joining the company, and in accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee approved the granting of equity inducement awards to each of Mr. Miele and Mr. Shin, in each case effective as of May 29, 2026 (collectively, the "Inducement Awards"). The Inducement Awards were made outside of the company's current equity plan but are subject to terms and conditions generally consistent with those in the company's Stand‑Alone Inducement Restricted Stock Unit Agreement and the company's 2026 Equity Incentive Plan.
Paul Miele Inducement Award
Mr. Miele was granted 650,000 restricted stock units ("RSUs") covering shares of the company's common stock. One fourth (1/4) of the underlying shares subject to the RSU award will vest on April 30, 2027 and will continue to vest as to one-fourth (1/4) of the underlying shares subject to the RSU award on each yearly anniversary of such date, subject in each case to Mr. Miele's continued employment through the applicable vesting date.
In addition, Mr. Miele was granted 650,000 performance based restricted stock units ("PSUs") (at target) covering shares of the company's common stock. The PSUs have a performance period ending on the last day of the company's 2028 fiscal year and will vest based on the achievement of performance criteria and other terms as determined by the Board of Directors or its Compensation Committee for performance based restricted stock units granted to other similarly situated senior executives, subject to Mr. Miele's continued employment and the terms of the applicable award agreement.
David Shin Inducement Award
Mr. Shin was granted 375,000 restricted stock units ("RSUs") covering shares of the company's common stock. One‑fourth (1/4) of the underlying shares subject to the RSU award will vest on January 29, 2027 and will continue to vest as to one-fourth (1/4) of the underlying shares subject to the RSU award on each yearly anniversary of such date, subject in each case to Mr. Shin's continued employment through the applicable vesting date.
In addition, Mr. Shin was granted 375,000 performance based restricted stock units ("PSUs") (at target) covering shares of the company's common stock. The PSUs have a performance period ending on the last day of the company's 2028 fiscal year and will vest based on the achievement of performance criteria and other terms as determined by the Compensation Committee for performance based restricted stock units granted to other similarly situated senior executives of the company, subject to Mr. Shin's continued employment and the terms of the applicable award agreement.
About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.
Media Contact
Taylor Bould
Communications Specialist, Accuray
+1 (608) 830-3604
tbould@accuray.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-incorporated-reports-inducement-award-under-nasdaq-listing-rules-302786070.html
SOURCE Accuray Incorporated